<DOC>
	<DOCNO>NCT00750815</DOCNO>
	<brief_summary>Cyclophosphamide chemotherapy agent know activity myeloma . The new regimen test study call CVDD contains Cyclophosphamide Bortezomib ( VELCADE ) , Pegylated Liposomal Doxorubicin ( DOXIL® , PLD ) , Dexamethasone ( VDD ) . The purpose study determine addition another type chemotherapy agent , Cyclophosphamide , regimen VDD ( CVDD ) well tolerate improve response rate myeloma . We also find high safe dose study drug take together patient tolerate , long take multiple myeloma patient respond take study drug long response last .</brief_summary>
	<brief_title>Cyclophosphamide , VELCADE , DOXIL , Dexamethasone , ( CVDD ) Newly Diagnosed Patients With Multiple Myeloma ( MM )</brief_title>
	<detailed_description>The first cohort 3 participant enrol Phase I study receive dose level 1 . A full safety evaluation conduct participant complete one cycle ( 21 day ) combination therapy . Further patient accrual suspend safety data evaluate dose level . Dose escalation subsequent patient proceed dose level 2 , 3 4 follow : - If dose limit toxicity ( DLT ) report first 3 participant dose level , dose level consider safe 3 participant enrol next dose level . If 1/3 participant cohort dose level DLT , dose level expand obtain 6 evaluable participant . - If &gt; 1 3 participant cohort experience DLT , dose level consider safe . No dose escalation take place , immediate low dose level consider maximum plan dose ( MPD ) 6 patient enrol dose level . Otherwise , expand immediate low dose level 6 evaluable patients* . - If &lt; 2 participant DLT among expanded cohort 6 evaluable participant , cohort 3 participant enrol next high dose level . - If 2 participant DLT among expanded cohort 6 evaluable participant , dose level consider safe . No dose escalation take place , immediate low dose level consider MPD 6 patient enrol dose level . Otherwise , expand immediate low dose level 6 evaluable patients* . - * If DLT occur 1 patient expand dose cohort , dose level consider MPD . Otherwise , dose de-escalated similar fashion MPD reach .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Understand voluntarily sign informed consent form ; equal great 18 year age time consent Able adhere study visit schedule protocol requirement Diagnosed active multiple myeloma Measurable myeloma paraprotein level serum ( ≥ 0.5 g/dL ) urine ( ≥ 0.2 g excrete 24hour urine collection sample ) , serum involve free light chain ( &gt; 10mg/dl ) provide k/l ratio abnormal Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Performance status 3 allow related bony disease . Bilirubin ≤ 1.5x upper limit normal ( ULN ) Liver enzymes : alanine transaminase ( ALT ) aspartic transaminase ( AST ) ≤ 2.5 x ULN . In presence liver metastasis , AST / ALT , alkaline phosphatase total bilirubin must exceed 3x upper limit normal ( i.e . : must ≤ 3x ULN ) . Adequate bone marrow function : Absolute neutrophil count ( ANC ) ≥ 1,000 cells/mm³ ( 1.0 x 10^9/L ) . Patients bone marrow &gt; 50 % plasma cell permit neutrophil count &lt; 1,000 cells/mm³ . Platelets ≥ 100,000 cells/mm³ . Patients bone marrow &gt; 50 % plasma cell permit Platelet count ≤ 100 , 000 cells/mm³ Hemoglobin &gt; 8 g/dL ( transfusion allow increase Hgb ) Adequate renal function : Creatinine ≤ 2.5 mg/dL Must 2d echocardiogram multigated acquisition ( MUGA ) scan indicate leave ventricular ejection fraction ( LVEF ) ≥ 50 % within 42 day prior first dose study drug . A MUGA scan 2 Echocardiogram may use , test must use throughout study ) evaluate LVEF . Women childbearing potential ( WCBP ) † must negative serum urine pregnancy test 10 14 day prior start therapy . Patients reproductive potential must use adequate contraceptive method treatment 3 month complete treatment . In addition , sexually active WCBP must agree use adequate contraceptive method per requirement outline protocol document . Patients treat local radiotherapy without concomitant exposure steroid , pain control management cord/nerve root compression , eligible . 4 week must lapse since last date radiotherapy . Patients require concurrent radiotherapy entry protocol defer radiotherapy complete 4 week pass since last date therapy . Ongoing severe infection require intravenous antibiotic treatment Life expectancy &lt; 3 month Prior malignancy , except ; adequately treat basal cell squamous cell skin cancer , insitu cervical cancer , cancer participant diseasefree least 5 year . Concurrent prostate cancer patient receive therapy consider exclusion prostatic specific antigen ( PSA ) stable 3 year . Solitary bone solitary extramedullary plasmacytoma evidence plasma cell dyscrasia Patients receive therapeutic dosage steroids multiple myeloma Myocardial infarct within 6 month enrollment , New York Heart Association ( NYHA ) Class II great heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , clinically significant pericardial disease , electrocardiographic evidence acute ischemic active conduction system abnormality Uncontrolled medical problem diabetes mellitus , coronary artery disease , hypertension , unstable angina , arrhythmia , pulmonary , hepatic renal disease unless renal insufficiency felt secondary multiple myeloma Any serious medical condition , laboratory abnormality , psychiatric illness would prevent patient signing informed consent form Pregnant breastfeeding female . Lactating female must agree breastfeed . Any condition , include presence laboratory abnormality , place participant unacceptable risk he/she participate study confounds ability interpret data study . Prior chemotherapy multiple myeloma , except radiation symptomatic bony disease , plasmapheresis hyperviscosity , kyphoplasty and/or vertebroplasty History hypersensitivity reaction attribute conventional formulation doxorubicin hydrochloride ( HC1 ) component DOXIL® Prior anthracycline dose exceed 360 mg/m² doxorubicin ( include DOXIL ) 720 mg/m² epirubicin Grade 2 high peripheral neuropathy clinical examination within 14 day enrollment Polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy , skin change ( POEMS ) syndrome plasma cell leukemia Hypersensitivity bortezomib , boron mannitol Has receive investigational drug within 14 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>B Cell</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>plasma</keyword>
	<keyword>bone marrow</keyword>
</DOC>